Hervé Bonnefoi

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index

  JAMA Network Open · 2025-11-03 · 2 citations

• Reply to: Germline and Somatic <i>BRCA1/2</i> Mutations in Breast Cancer Treatment Strategies

  JCO Precision Oncology · 2025-09-01

• Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial

  The Lancet · 2025-07-31 · 14 citations

• Abstract PS9-06: Tracking structural variants in ctDNA using a high-sensitivity assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trial

  Clinical Cancer Research · 2025-06-13

• <i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis

  JCO Precision Oncology · 2025-04-01 · 2 citations

• Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial

  npj Breast Cancer · 2025-03-07 · 7 citations

• Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial

  The Lancet Oncology · 2025-02-17 · 21 citations

• Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping

  Cancer Cell · 2025-02-01 · 24 citations

• De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

  UNC Libraries · 2025-01-23 · 17 citations

• Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer

  New England Journal of Medicine · 2025-01-15 · 116 citations

• Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update

  Journal of Clinical Oncology · 2024-09-11 · 30 citations

• Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer

  JAMA Oncology · 2024-08-15 · 11 citations